Keeping the Romance Vital: Sexuality and Cancer ©
laurabbook@gmail.com2019-04-18T09:27:59-07:00*April 2019* Written by Tess Taft, MSW, LICSW, and oncology psychotherapist.© The feelings related to sexuality when it comes to
18
April 2019
17
March 2019
Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR
laurabbook@gmail.com2019-03-17T11:39:10-07:00*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of
17
March 2019
Loving Ourselves into Health©
laurabbook@gmail.com2019-03-17T11:26:29-07:00*February 2019* Written by Tess Taft, MSW, LICSW, and oncology psychotherapist.© Any real threat to our lives forces us to
17
March 2019
Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance
laurabbook@gmail.com2019-03-17T11:10:16-07:00*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the
14
March 2019
Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon
laurabbook@gmail.com2019-03-14T10:04:41-07:00*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for
14
March 2019
Talking to Your Children About Cancer©
laurabbook@gmail.com2019-03-17T11:17:19-07:00*March 6, 2019* by Tess Taft, MSW, LICSW, Oncology Family Therapist.© “I feel like I’m doing something terrible to my family
3
February 2019
Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients
laurabbook@gmail.com2019-02-11T13:17:42-07:00*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung
3
February 2019
A cancer researcher reflects on the evolution of lung cancer therapies
laurabbook@gmail.com2019-02-03T11:20:23-07:00*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to
3
February 2019
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC
laurabbook@gmail.com2019-02-03T11:06:16-07:00*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had
5
January 2019
OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?
laurabbook@gmail.com2019-01-05T11:08:03-07:00*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.